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quality-adjusted life years (QALYs) were calculated from utility data sourced from 
the published literature. The cost-effectiveness was reported as an incremental 
cost-effectiveness ratio (ICER). To assess uncertainty, univariate deterministic and 
multivariate probabilistic sensitivity analyses (PSA) were performed. Results: 
Compared to the DPP4i class, dapagliflozin was associated with 0.023 incremental 
QALYs (95% CI: -0.058, 0.105), at an additional cost of £253 (95% CI: -£302, £741). This 
resulted in an ICER of £10,995 per QALY gained. The incremental cost associated with 
dapagliflozin was primarily due to the additional drug acquisition cost, whereas the 
QALY gain estimated was associated with superior weight reduction and its impact 
on health-related quality of life for dapagliflozin relative to the DPP4i’s. Univariate 
analyses demonstrated that the ICER was most sensitive to varying the weight 
change parameter for the comparator DPP4i’s according to the 95% credible intervals 
in the NMA, giving ICER estimates ranging from £3,937 to £16,727. Dapagliflozin 
had a 59% probability of being cost-effective versus DPP4i’s at a willingness-to-
pay threshold of £20,000 per QALY gained. ConClusions: Dapagliflozin as triple 
therapy in combination with met+SU was shown to be a cost-effective treatment 
option from a UK health care perspective for patients with T2DM who are inad-
equately controlled on met+SU.
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objeCtives: To assess the cost-effectiveness of saxagliptin, a dipeptidyl pepti-
dase-4 inhibitor (DPP4i), compared to the glucagon-like peptide-1 (GLP-1) analogues, 
exenatide twice-daily or lixisenatide, when added to insulin (±metformin) for the 
treatment of patients with type 2 diabetes mellitus (T2DM) who are inadequately 
controlled on insulin. Methods: The validated CARDIFF diabetes model was used 
to conduct the analyses. Clinical inputs for the model were sourced from a system-
atic review and network meta-analysis (NMA), which found that the treatments 
were similarly effective at lowering HbA1c and that the GLP-1 analogues resulted 
in greater and clinically relevant weight loss. A UK health care perspective was 
used for costs, and quality-adjusted life years (QALYs) were calculated from util-
ity data sourced from the published literature. To assess uncertainty, univariate 
deterministic and multivariate probabilistic sensitivity analyses (PSA) were per-
formed. Results: Saxagliptin was found to dominate lixisenatide in the base case, 
being associated with lower costs (-£472 [95%CI: -1,378, -223]) and slightly more 
QALYs (0.010 [95%CI: -0.040, 0.076]). Saxagliptin was less costly (-£1,402 [95%CI: 
-£1,932, -£1,218]) and slightly less effective (-0.012 QALYs [95%CI: -0.054, 0.035]) than 
exenatide twice-daily. The lower costs associated with saxagliptin were primarily 
due to the lower drug acquisition costs. The estimated QALY differences were small 
and associated with the impact of weight reduction on health-related quality of 
life. Univariate sensitivity analyses demonstrated that the results were most sensi-
tive to varying the HbA1c treatment effect and the effect of saxagliptin on weight 
change. The PSA estimated that saxagliptin had a 70.4% and 34.3% probability of 
being dominant, and a 99.4% and 100% probability of being cost-saving compared to 
lixisenatide and exenatide twice-daily, respectively. ConClusions: Saxagliptin as 
add-on to insulin was shown to be a cost-saving treatment option from a UK health 
care perspective for patients with T2DM who are inadequately controlled on insulin.
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objeCtives: To conduct a systematic review of cost-effectiveness, cost-utility and 
cost-benefit studies of new inhibitors of DPP-4 for diabetes treatment versus other 
antidiabetics. Methods: We searched the CRD York, NICE Health Technology 
Assessment, Tufts CEA Registry, and MEDLINE (PubMed) databases, and grey litera-
ture through 2014 to identify cost-effectiveness, cost-utility and cost-benefit studies 
of new inhibitors of DPP-4 versus other antidiabetics for diabetes treatment. Three 
investigators independently reviewed all potentially relevant titles and abstracts (1st 
screening), and subsequently screened full-text articles (2nd screening), according to 
pre-established inclusion criteria. We restricted our sample to studies with a lifetime 
or near-lifetime horizon, and adopting either a societal or a health care perspective. 
The studies should be available as a full-text publication and published in English, 
French, Spanish, or Portuguese language. A critical appraisal of the methodology and 
reporting was performed using the 35item version of the BMJ checklist. Results: 
A total of 57 studies were identified. From these, 17 studies were accepted after the 
1st screening, of which 11 were accepted after the 2nd screening. All selected studies 
consisted in cost-utility analyses. Most studies were based on a single randomized 
trial per therapy. Saxagliptin was assessed in 6 studies, Sitagliptin in 4, and vilda-
gliptin in 1. Liraglutide was cost-effective versus sitagliptin as second line therapy 
(ranged from 12,164 to 27,289€ /QALY across countries). Saxagliptin (ranged from 
771 to 10,065 € /QALY across countries), Sitagliptin (ranged from 5,949 € /QALY to 
20,350 € /QALY across countries) and vildagliptin (ICER of 9,072 € / QALY in Portugal) 
were cost-effective versus sulfonylureas as second line therapy. ConClusions: 
According to commonly accepted thresholds, there is consistent evidence about the 
cost-effectiveness of DDP-4 inhibitors as second line therapy for diabetes type 2. 
Though, more evidence (including head-to-head) is necessary to define which DDP-4 
inhibitor is the most cost-effective.
and SU would generate substantial cost savings in France. Canagliflozin 300mg 
showed similar outcomes to liraglutide, suggesting that the treatments are similar 
in effectiveness, and is thus likely to be a highly cost-effective treatment option.
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objeCtives: We have developed a model to evaluate type-2 diabetes prevention 
interventions. The model allows flexible layering of multiple interventions in order to 
determine the optimal combination of strategies for maximal cost-effectiveness. Our 
objective was to demonstrate the utility of the model for analysis of multiple inter-
ventions in different population sub-groups. Methods: A model of type-2 diabetes 
prevention was developed using a micro-simulation framework. Individual patients 
have simulated trajectories of metabolic factors such as BMI, HbA1c, systolic blood 
pressure and total cholesterol, and can be diagnosed with diabetes, cardiovascular 
disease, cancer, osteoarthritis or microvascular complications of diabetes over the 
course of a lifetime. Interventions targeting metabolic factors influence the likelihood 
of patients developing ill health and dying prematurely. Five interventions were cho-
sen for layering analyses: soft drinks taxation; retail policy; a workplace intervention; 
an educational intervention aimed at deprived individuals; and a diabetes screening 
programme followed by intensive intervention for high risk individuals. Eight dif-
ferent intervention combinations were modelled, using the assumption of either 
additive, synergistic or antagonistic effects in individuals subject to multiple interven-
tions. Results: All interventions generated cost-savings and QALY gains, with the 
screening intervention performing particularly well, followed by the soft drinks tax. 
Combining interventions results in roughly additive effects; this holds whether the 
layering is additive, synergistic or antagonistic due to the relatively low proportions 
of individuals subject to multiple interventions. Certain pairs of interventions were 
found to be almost as cost-effective as combining all five interventions, in particular, 
a soft drinks tax combined with a screening programme is likely to be one of the most 
cost-effective options. ConClusions: The SPHR Diabetes Model is a useful tool for 
analysing the cost-effectiveness of different diabetes prevention interventions, either 
singly or in combination. This will enable development of intervention strategies 
tailored to the needs of the target population.
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objeCtives: To explore the cost-effectiveness of dapagliflozin, the first-in-class 
sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared to the dipeptidyl 
peptidase-4 inhibitor (DPP4i) class, as monotherapy for the treatment of type 2 
diabetes mellitus (T2DM) that is inadequately controlled by diet and exercise alone 
in patients who are intolerant to metformin. Methods: The validated CARDIFF 
diabetes model was used. Clinical inputs for the model were sourced from a sys-
tematic review and network meta-analysis (NMA) in monotherapy. A UK health 
care perspective was used for costs, and quality-adjusted life years (QALYs) were 
calculated from utility data in the published literature. A range of assumptions to 
reflect potential clinical practice were utilised. Alterations to the HbA1c switching 
threshold and assumptions on weight extrapolation were considered, in order to 
investigate the impact of different profiles of weight change and longer-term evi-
dence for the maintenance of weight loss. The cost-effectiveness was reported as an 
incremental cost-effectiveness ratio (ICER). Results: When the model assumptions 
were varied around the HbA1c switching threshold and around the profile of main-
tenance of weight loss to better reflect clinical practice, the ICER point estimates 
ranged from £1,847 to £30,795. The lowest ICER point estimate was associated with 
an assumption of maintaining the weight differential that is created at treatment 
initiation, which is generated by the better weight profile of dapagliflozin compared 
to DPP4i, over the whole time horizon. The highest estimate arose when the weight 
differential was maintained for 2 years and there was a higher switching threshold 
for initiating insulin. ConClusions: Dapagliflozin monotherapy has potential as 
a cost-effective treatment option from a UK health care perspective for patients 
with T2DM who are intolerant to metformin and are inadequately controlled by 
diet and exercise alone, based upon a range of explored scenarios. This study also 
demonstrates the value of performing scenario analysis to inform decision-making.
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objeCtives: To assess the cost-effectiveness of dapagliflozin, the first-in-class 
sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared to the dipeptidyl 
peptidase-4 inhibitor (DPP4i) class, when used as triple oral therapy in combina-
tion with metformin and a sulphonylurea (met+SU) for the treatment of patients 
with type 2 diabetes mellitus (T2DM) who are inadequately controlled on met+SU 
alone. Methods: The validated CARDIFF diabetes model was used. Clinical 
inputs for the model were sourced from a systematic review and network meta-
analysis (NMA) in triple therapy that found clinically relevant differences between 
dapagliflozin and DPP4i’s. A UK health care perspective was used for costs, and 
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reduction in diabetes related complications and the lower frequency of SMBG 
tests. Remaining extra annual costs for SAP were 1,258 € per patient. When indirect 
costs were considered, the ICER was reduced to 23,300 € per QALY. ConClusions: 
Using a well-accepted simulation model in an uncontrolled T1DM, projection of 
the improvement in HbA1c of SAP versus CSII translated into cost-effective ratio, 
generally considered as very good value for money in France. Extensive sensitivity 
analysis on key drivers confirmed the robustness of results under a wide range 
of assumptions.
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objeCtives: To investigate the costs and cost-effectiveness of a short message 
service (SMS) intervention to prevent the onset of type 2 diabetes mellitus (T2DM) 
in subjects with impaired glucose tolerance (IGT). Methods: A Markov model was 
developed to simulate the cost and effectiveness outcomes of the SMS interven-
tion and usual clinical practice from the health service provider’s perspective. The 
annual transition probabilities between health states were taken from several 
data sources, including Diabetes Prevention Program and Diabetes Prevention 
Program Outcome Study. The direct program costs and the two-year SMS interven-
tion costs were evaluated in subjects with IGT. All costs were expressed in year 
2011 U.S. dollars. The incremental cost-effectiveness ratio were calculated as cost 
per T2DM onset prevented, cost per life year gained and cost per quality adjusted 
life year (QALY) gained. Both base-case scenario and sensitivity analysis were 
conducted. Results: Within the two-year trial period, the net intervention cost 
of the SMS group was $42.03 per subject. The SMS intervention managed to reduce 
5.05% onset of diabetes, resulting in saving $118.39 per subject over two years. 
In the lifetime model, the SMS intervention dominated the control by gaining 
an additional 0.071 QALY and saving $1020.35 per person. The SMS interven-
tion remained dominance in all sensitivity analyses. ConClusions: This study 
revealed that the SMS intervention for subjects with IGT had the superiority of 
lower monetary cost and a considerable improvement in preventing or delaying 
the T2DM onset.
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objeCtives: To evaluate the cost of using the first-in-class sodium-glucose co-
transporter-2 (SGLT-2) inhibitor dapagliflozin compared to the glucagon-like pep-
tide-1 (GLP-1) analogue lixisenatide, when added to insulin for the treatment of 
patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled on 
insulin alone. Methods: Bucher indirect comparisons and a network meta-analy-
sis were performed in the add-on to insulin population with regards to the key T2DM 
outcomes of HbA1c, weight and hypoglycaemia. Dapagliflozin had similar treat-
ment effects to lixisenatide, with no statistically significant differences between 
dapagliflozin and lixisenatide in these outcomes. Therefore, a cost-minimisation 
analysis over a 1-year time horizon was developed from a UK health care perspec-
tive. Drug and administration costs, including a nurse consultation, were considered 
in the model. Drug costs were those of the British National Formulary (September 
2013), device costs were taken from the Information Services Division Drug Tariff 
2013 and the cost of a nurse consultation was estimated using the Unit Costs of 
Health and Social Care report compiled by the Personal Social Services Research 
Unit. The application of an annual discount rate of 3.5% and use of a longer time 
horizon (up to 5 years) were explored in scenario analyses. Results: Dapagliflozin 
was associated with a yearly cost of £476.96 per patient. The cost per patient for 
lixisenatide was £765.76 in the first year and £752.07 in subsequent years. Therefore, 
dapagliflozin was cost-saving compared to lixisenatide, driven by the difference 
in drug and administration costs. Applying the annual discount rate and using a 
longer time horizon, dapagliflozin was associated with savings of £1,255.30 over 5 
years compared to lixisenatide. ConClusions: Dapagliflozin in combination with 
insulin was shown to be a cost-saving treatment option compared to lixisenatide 
from a UK health care perspective for patients with T2DM who are inadequately 
controlled on insulin alone.
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objeCtives: Acromegaly is a chronic and debilitating disease, which can lead 
to significant increases in health care costs. The objective of the present study 
was to undertake an economic evaluation of Lanreotide Autogel compared with 
Octreotide LAR in the management of acromegaly in the Greek health care set-
ting. Methods: A cost minimization model was developed for the analysis which 
only considers the costs of treatment, as the two drugs have equal efficacy. The 
time horizon was 30 years; future costs were discounted at 3.5%. In addition, 
a budget impact analysis was conducted, with a time horizon of 5 years. The 
perspective for both analyses was that of Social Insurance. Data on resource use 
(administration setting, drug wastage and time required for the administration of 
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objeCtives: To synthesize and analyze the available information on the thera-
peutic value of dipeptidyl peptidase-4 inhibitors (DPP-4) for the treatment of type 2 
diabetes mellitus (T2DM) from the point of view of their efficiency or cost-effective-
ness. Methods: A systematic review of national (MEDES, IBECS) and international 
(MedLine/PubMed, Cochrane Library, ISI WOK, SCOPUS) databases was performed. 
Eligible studies were economic evaluations (cost-effectiveness, cost-utility and cost-
benefit analysis) comparing costs and clinical benefits of two alternatives for the 
T2DM treatment including DPP-4 inhibitors, published in English or Spanish until 
June 2013. Studies providing data concerning costs and/or disease burden only were 
excluded. Results: Of 1,634 publications initially selected, 284 were excluded by 
duplicate review, 1,330 by title/abstract review and 8 by criteria accomplishment. A 
total of 12 publications [1 conducted in 6 countries including Spain, 4 in Europe, 4 
in USA and 3 in others] were selected. All studies were cost-effectiveness or cost-
utility analysis [discrete-event simulation (n= 8), Markov (n= 3) and others (n= 1)] 
Time horizon ranged from one year (n= 1) to lifetime (n= 7), considering 20 years 
(n= 1), 35 years (n= 2), and 40 years (n= 1). National Health System perspective was 
adopted in all publications (n= 12). One study did not include a sensitivity analysis. 
Results showed that T2DM therapy with DPP-4 inhibitors and metformin resulted 
cost-effective compared with sulfonylureas plus metformin in all countries which 
were evaluated (Sweden, UK, Germany, Portugal, Austria, Finland, Spain, USA and 
Argentina). Although DPP-4 inhibitors cost was higher compared with sulfonylureas, 
DPP-4 inhibitors plus metformin were associated to higher clinical benefits versus 
sulfonylureas plus metformin in terms of decreasing hypoglycemia incidence and 
T2DM complications. ConClusions: DPP-4 inhibitors added to metformin are a 
cost-effective alternative compared with sulfonylureas plus metformin in T2DM 
patients, mainly due to a lower hypoglycemia incidence and T2DM complications.
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objeCtives: The main objective of this study was to estimate the health-economic 
impact of sensor augmented pump (SAP) compared to pump therapy alone (CSII) of 
type 1 diabetes (T1DM) in the UK. Methods: The Core Diabetes Model was used 
to project the incidence of diabetes-related complications over a lifetime horizon, 
based on A) a published meta-analysis comparing SAP versus CSII, and B) a real 
life observational study. The meta-analysis showed that for the analysed cohort of 
T1DM with average baseline HbA1c of 10%, every day use of SAP led to a reduction 
of -1.49% versus -0.62% HbA1c, for CGM and CSII respectively. The mean baseline 
age of the simulated cohort was 27 years, with a mean duration of diabetes of 13 
years. SAP effects also included a decrease in the annual rate of major hypoglycae-
mic events from 2.2 events per 100 patients’ month for CSII to 0. The quality of life 
was adjusted for a reduced fear of hypoglycaemic event in the SAP arm. Sensitivity 
analyses were carried out on several key parameters. Results: The incremental 
cost-effectiveness ratio (ICER) was 16,986 GBP (£) per Quality Adjusted Life Year 
gained (QALY). The improvement in discounted QALY was 3.1 years in favour of SAP. 
Additional SAP related costs were partially offset by the savings due to the reduction 
in diabetes related complications and the lower frequency of SMBG tests. Remaining 
extra costs due to SAP were on average 1,143£ per year. When a societal perspective 
was considered, ICER was reduced to 8,462 £ per QALY. ConClusions: Projection 
of the improvement in HbA1c of SAP versus CSII translated into cost-effective ratio, 
generally considered as very good value for money in the UK. Extensive sensitivity 
analysis on key drivers confirmed the robustness of results under a wide range of 
assumptions.
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objeCtives: The main objective of this study was to estimate the health-economic 
impact of sensor augmented pump (SAP) compared to pump therapy alone (CSII) 
in uncontrolled type 1 diabetes (T1DM) in France. Methods: The Core Diabetes 
Model was used to project the incidence of diabetes-related complications over 
a lifetime horizon, based on a recently performed meta-analysis comparing SAP 
versus CSII. The meta-analysis showed that for the analysed cohort of T1DM using 
exclusively Medtronic devices with average baseline HbA1c of 9%, 70% use of SAP 
led to a reduction of -0.88% versus -0.47% HbA1c, for SAP and CSII respectively. 
The mean baseline age of the simulated cohort was, according to a French typi-
cal TD1M population, 36 years, with a mean duration of diabetes of 17 years. The 
quality of life was adjusted for a reduced fear of hypoglycaemic event in the SAP 
arm. Sensitivity analyses were carried out on several key parameters. Results: 
The incremental cost-effectiveness ratio (ICER) was 27,796 € per Quality Adjusted 
Life Year gained (QALY). The improvement in discounted QALY was 1.27 years in 
favour of SAP. Undiscounted life expectancy was increased by 1 year for SAP versus 
CSII. Additional SAP related costs were partially offset by the savings due to the 
